Zoetis (ZTS) cut its 2026 outlook, now guiding for a 1% to 3% organic revenue decline, a shift that sharpened investor focus on its valuation and on slower growth compared with healthcare peers.
Recent trading has been rough for Zoetis, with the share price down 8.3% over the past 90 days and the year-to-date share price return falling 42.1% to US$72.97. The 5 year total shareholder return has declined 61.1%, indicating that momentum has been fading rather than building.
Pressure test Zoetis against other potential opportunities by scanning our curated list of 31 high quality undervalued stocks featuring companies with solid cash flows and strong balance sheets.
Zoetis runs a large, global animal health franchise, yet the stock has been reset after the outlook cut and a period of weak returns. The key issue now is simple: Does the current valuation fairly reflect that business quality?
Most Popular Narrative: 21.5% Undervalued
Against Zoetis’ last close at $72.97, the most followed valuation story points to a fair value of $92.92, which frames the current reset very differently.
On one hand it is not a business that is expected to grow much; on the other hand, it is also not viewed as likely to collapse catastrophically. Double-edged sword. The company cites generics as a potential risk in its financial statements. I am not sure how much of this could be attributable to the 11% year-on-year decline in Pet segment revenues, but this is something to watch out for if you are interested in investing in the business.
Want to understand why this narrative still sees upside in Zoetis after a sharp share price fall? The answer sits in the balance between steady margins, measured earnings growth and the profit multiple that underpins that $92.92 figure.
According to ValueInvestingSubstack, the fair value hinges on a business that grows earnings at a single digit pace, keeps profitability solid and supports that with ongoing demand from pets and livestock worldwide. The narrative links those assumptions to a discount rate of 7.108% and then weighs that against Zoetis’ current share price performance, which has been weak over 1, 3 and 5 years.
The same story highlights a few pressure points that readers may want to weigh carefully. Earnings growth over the past year of 1.8% trails the 5 year average of 6.9%. Forecast profit expansion of 3.5% and revenue growth of 2.3% per year are both below broader US market expectations. The analyst flags high leverage, funding buybacks with roughly $9b of total debt, alongside customer concentration and exposure to generics.
Set against that, the narrative leans on quality markers. Zoetis reports net income of $2,637.0m on revenue of $9,525.0m, has current net profit margins of 27.7% that are slightly higher than last year, and scores as having high quality earnings. The business pays a 2.91% dividend, is considered to have a seasoned board with an average tenure of 9.1 years and an experienced management team, and is forecast to show very high return on equity in three years, even if that metric is influenced by leverage.
Where the story becomes most interesting is the gap between market pricing and several valuation markers. The narrative labels Zoetis as good value overall, trading at good value compared to peers and the wider pharmaceuticals group. It also flags that the stock trades 64% below a future cash flow value estimate of $202.45 and at a discount to an estimated fair P/E ratio of 21.8x, even though P/E is not the primary lens in this discussion.
Investors reading this may wish to compare that narrative fair value of $92.92 and the implied 21.5% discount with their own expectations for growth in the companion animal and livestock businesses, as well as their comfort with debt funded capital returns. The key question is whether Zoetis’ earnings profile and balance sheet justify the gap between the current share price, the narrative fair value and the higher future cash flow value estimate.
Result: Fair Value of $92.92 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
Still, Zoetis faces real pressure if the 11% drop in US Companion Animal revenue worsens, or if customer and product concentration magnifies any competitive hit from generics.
Find out about the key risks to this Zoetis narrative.
Next Steps
Sentiment on Zoetis is clearly mixed, with real risks on one side and clear potential on the other. Move quickly, look through the detailed numbers, weigh the threats against the upside, and ground your own view in the balance of 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Zoetis?
If Zoetis has sharpened your focus on valuation and quality, broaden your watchlist with a few targeted angles that can surface fresh opportunities fast.
- Target resilience first and stress test your portfolio ideas against a 11 resilient stocks with low risk scores designed to highlight businesses with more durable profiles.
- Hunt for pricing gaps by scanning a 31 high quality undervalued stocks that filters for quality companies trading below their estimated worth.
- Spot potential future leaders early by reviewing a 16 high quality undiscovered gems that focuses on strong fundamentals before the crowd pays attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Zoetis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
